Investorsmay be trackingfundamental and technical data for Interleukin Genetics, Inc. (OTCPK:ILIU). The company has a current Value Composite Score of 100. Using a scale from 0 to 100, a lower score would represent an undervalued company and a higher score would indicate an expensive or overvalued company. This ranking was developed by James OShaughnessy using six different valuation ratios including price to book value, price to sales, EBITDA to EV, price to cash flow, price to earnings, and shareholder yield.

Shifting the focus to some ROIC (Return on Invested Capital) numbers, Interleukin Genetics, Inc. (OTCPK:ILIU)s ROIC is -15.844075. The ROIC 5 year average is -8.915091 and the ROIC Quality ratio is -0.849448. ROIC is a profitability ratio that measures the return that an investment generates for those providing capital. ROIC helps show how efficient a company is at turning capital into profits. ROIC may be a good measure to view when examining whether or not a company is able to invest wisely. ROIC may also be an important metric for the value investor who is trying to determine the companys moat.

Traders may also be following some financial ratios for Interleukin Genetics, Inc. (OTCPK:ILIU). Currently, the firm has a Gross Margin (Marx) ratio of 0.191377. This number is based off of the research by University of Rochester professor Robert Novy-Marx. Marx believed that a high gross income ratio was a sign of a quality company. Looking further, Interleukin Genetics, Inc. has a Gross Margin score of 5. This score is based on the Gross Margin (Marx) metric using a scale from 1 to 100 where a 1 would be seen as positive, and a 100 would be regarded as negative. Investors may also be paying increased attention to the EV for Interleukin Genetics, Inc. (OTCPK:ILIU). The company currently has an EV or Enterprise Value of 19196. The EV helps show how the market assigns value to a company as a whole. EV is a modification of market cap, as it incorporates debt and cash for assessing a firms valuation. Watching a firms EV may be useful when comparing companies with different capital structures. EV can help investors gain a truer sense of whether a company is undervalued or not.Interested investors may be looking at the Magic Formula (MF Rank) on shares of Interleukin Genetics, Inc. (OTCPK:ILIU). Currently, the company has an MF Rank of 17026. Successful hedge fund manager Joel Greenblatt developed the Magic Formula which was introduced in his book The Little Book That Beats the Market. Greenblatt was focused on a method for identifying bargains when purchasing company shares. This included spotting companies that earn more relative to the stock price, or companies with a high earnings yield. The Magic Formula may help spot good, healthy companies. The MF is calculated using earnings yield and ROIC ratios. In general, investors may be searching for stocks with the lowest combined MF Rank.

Continued here:
Stock Concentration on Shares of Interleukin Genetics, Inc. (OTCPK:ILIU) - Lenox Ledger